



Updates on Novel Antimicrobials Agents and Strategies against Pathogenic Bacteria, 2nd Edition

Guest Editors:

Dr. Marco Maria D'Andrea

Department of Biology, University of "Tor Vergata", 00133 Rome, Italy

Dr. Alberto Antonelli

Department of Experimental and Clinical Medicine, University of Florence; Microbiology and Virology Unit, Careggi University Hospital; 50134 Florence, Italy

Deadline for manuscript submissions:

closed (31 August 2021)

Message from the Guest Editors

Dear Colleagues,

We are very excited to announce the second edition of the Special Issue "Updates on Novel Antimicrobial Agents and Strategies Against Pathogenic Bacteria". The breadth of antibiotic resistance phenomena is currently undermining the effectiveness and the usefulness of these very precious molecules for the battle against bacterial infectious diseases. There is currently a more pronounced need to discover novel antibiotics and develop innovative antimicrobial approaches for the successful control of bacterial infections.

The second edition of this Special Issue aims to provide an update on the current original approaches to fighting bacterial pathogens. It is expected that this Special Issue will collect research articles on new molecules and formulations with antimicrobial activity, including new conventional antibiotics of either synthetic or natural origin, modified drugs with augmented potency to be used alone or in synergy, innovative alternatives such as antimicrobial resistance inhibitors (e.g., β -lactamase inhibitors or efflux pump inhibitors), enzybiotics, and probiotics able to displace the pathogenic microflora.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)